OraSure Technologies, Inc.
OSUR Healthcare Medical Instruments & Supplies
OraSure Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $115.0 million, down 38.1% from fiscal 2024. In the quarter to June 2026, revenue fell 1.93%, EPS grew 134.6%, free cash flow fell 1.40% and total debt fell 8.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OSUR
OraSure Technologies, Inc. (OSUR) P/E ratio
OraSure Technologies, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2,895× (August 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 11.5× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 29.7× | (13.43%) |
| FY2018 | 34.4× | (5.61%) |
| FY2017 | 36.4× | 44.92% |
| FY2016 | 25.1× | (44.62%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SMTI Sanara MedTech Inc. compare | n/m |
| KRMD KORU Medical Systems, Inc. compare | n/m |
| OSUR OraSure Technologies, Inc. | n/m |
| ANGO AngioDynamics, Inc. compare | n/m |
| EMBC Embecta Corp. compare | 4.2× |
| PDEX Pro-Dex, Inc. compare | 13.8× |
| UTMD Utah Medical Products, Inc. compare | 22.7× |
| NNNN Anbio Biotechnology compare | — |
| ZJYL Jin Medical International Ltd. compare | — |
| Medical Instruments & Supplies industry median | 33.8× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)